Compare Eli Lilly And Co (LLY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vertex Pharmaceuticals Incorporated — how do they compare? Eli Lilly And Co trades at $1,153.77 (market cap $1.05T), while Vertex Pharmaceuticals Incorporated trades at $479.79 (market cap $123.26B). The key difference: Eli Lilly And Co is far larger — about 8.5× Vertex Pharmaceuticals Incorporated's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| LLY | VRTX | |
|---|---|---|
Market Cap | $1.05T | $123.26B |
Sector | Health | Health |
52-Week High | $1.24K | $529.59 |
52-Week Low | $625.65 | $366.54 |
Enterprise Value | $1.09T | $118.00B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,164.13, down 1.27% on the day, maintaining strong bullish technical momentum above key support levels. The company demonstrates exceptional fundamental performance with 2025 revenue reaching $65.18B and net income of $20.64B, representing a 31.66% margin. Recent acquisition of AtaiBeckley for up to $3.8 billion expands Lilly's neuroscience pipeline while the company continues to beat earnings expectations consistently.
Outlook remains positive with analyst consensus price target of $1,380 representing 18.5% upside potential. Key opportunities include sustained growth in diabetes and weight-loss drugs, while risks involve premium valuation metrics and integration challenges from recent acquisitions. The stock's technical setup suggests continued strength with institutional support evident from recent purchases.
Vertex Pharmaceuticals (VRTX) trades at $485.95, up 0.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported robust 2025 results with $12.00B revenue and $3.95B net income, maintaining high profitability margins. Recent news highlights a strategic $10B acquisition of Crinetics Pharmaceuticals, expected to add up to $5B in peak annual sales potential, positioning Vertex for growth in endocrinology treatments beyond its cystic fibrosis dominance.
The outlook for VRTX is positive, driven by earnings beats, expansion initiatives, and a consensus price target of $538 implying 11% upside. Risks include integration challenges from the Crinetics deal and reliance on pipeline success. With 86% of analysts rating it a Buy and solid cash flow trends, the stock offers growth potential but requires monitoring of acquisition execution and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
